Live
- NDA to fight Bihar polls with Nitish as CM face
- Allu Arjun refused to leave even after he was told of woman’s death
- Bareilly court summons Rahul Gandhi
- ‘Systematic conspiracy’ to undermine EC’s integrity: Kharge
- Popcorn tax slabs anger Congress
- India, Kuwait elevate ties to strategic level
- Nizamabad MP Dharmapuri Arvind and Jagtial MLA Dr. Sanjay Kumar Meet CM Revanth Reddy
- Hyderabad CP CV Anand Issues Stern Warning to Bouncers
- MP Laxman Criticizes Police Conduct, Calls for Support for Victims' Families
- Fire Breaks Out in Kachiguda-Chennai Egmore Express, Passengers Evacuated Safely
For The First Time In Medical History Cancer Vanishes From Patients During Drug Trial
- A modest clinical trial discovered that every single rectal cancer patient who got an experimental treatment saw their disease vanish.
- 18 patients took a medicine named Dostarlimab for six months in a limited clinical trial done by Memorial Sloan Kettering Cancer Center, and all of them saw their tumours shrink at the end.
A modest clinical trial discovered that every single rectal cancer patient who got an experimental treatment saw their disease vanish. This finding is believed to be a miracle and in the medical history.
According to sources,18 patients took a medicine named Dostarlimab for six months in a limited clinical trial done by Memorial Sloan Kettering Cancer Center, and all of them saw their tumours shrink at the end.
The specialist stated that Dostarlimab is a medicine made in a lab that functions as a surrogate for antibodies in the human body. Experts stated that the malignancy is undetectable by physical examination, endoscopy, positron emission tomography or PET scans, or MRI scans. This shows that Dostarlimab has the potential to be a 'possible' cure for one of the most lethal tumours.
As per reports, individuals in the clinical experiment had previously received treatments such as chemotherapy, radiation, and invasive surgery, all of which could cause bowel, urinary, and sexual dysfunction. The 18 patients expected to have to go through these surgeries as the next step in the research. However, they were surprised to learn that no more therapy was required.
Experts were astounded by the trial's outcomes, stating that total remission in every single patient is "unheard-of," reported The Times Of India. Experts praised the study because not all of the participants experienced serious side effects from the medication trial.
Dr. Alan P. Venook, a colon cancer specialist at the University of California stated that the complete remission in every single patient is "unheard of."
Patients in the trial were given Dostarlimab every three weeks for six months. The doctors added that it's worth noting that they were all in the same stage of cancer. The cancer had progressed locally in the rectum but had not migrated to other organs. They further added that no no patients had received chemoradiotherapy or surgery, and no cases of progression or recurrence had been recorded during follow-up.
